<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04599361</url>
  </required_header>
  <id_info>
    <org_study_id>01VSF18010</org_study_id>
    <secondary_id>DRKS00022175</secondary_id>
    <nct_id>NCT04599361</nct_id>
  </id_info>
  <brief_title>Health Care Analysis on Myocardial Revascularization in Patients With Chronic Coronary Heart Disease (CHD)</brief_title>
  <acronym>REVASK</acronym>
  <official_title>Health Care Analysis on Myocardial Revascularization in Patients With Chronic Coronary Heart Disease (CHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InGef - Institute for Applied Health Research Berlin GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Education Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsche Gesellschaft für Thorax-, Herz- und Gefäßchirurgie (DGTHG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stiftung Institut fuer Herzinfarktforschung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Köln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BARMER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Techniker Krankenkasse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>InGef - Institute for Applied Health Research Berlin GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myocardial infarction and chronic coronary heart disease (cCHD) are the most frequent causes&#xD;
      of death in Germany. Treatment options include widening of the narrowed / blocked coronary&#xD;
      vessel via catheter and stent or bypass surgery in which the narrowed vessel sites are&#xD;
      bridged. The &quot;German National Disease Management Guideline on cCHD&quot; helps doctors to decide&#xD;
      which treatment is most appropriate for the severity of vascular damage and possible&#xD;
      concomitant diseases of the patient. Nevertheless, there are other factors determining&#xD;
      treatment decision. For example, the equipment or preferences of the hospital or department&#xD;
      in which patients are admitted, play a role in the decision.&#xD;
&#xD;
      The aim of the REVASK project is to investigate whether and to what extent the collaboration&#xD;
      of cardiology and heart surgery specialists in so-called &quot;heart teams&quot; influences the&#xD;
      decision on therapy.&#xD;
&#xD;
      For this purpose, doctors and patients will be interviewed about how the treatment decision&#xD;
      was made and how satisfied both sides are with the outcome of the treatment and the decision.&#xD;
      In addition, claims data from several German health insurance companies (Techniker, BARMER,&#xD;
      Betriebs- und Innungskrankenkassen) will be analyzed. Treatment data, which is documented as&#xD;
      usual by the treating medical staff and passed on to the health insurance companies for&#xD;
      accounting purposes, is used. Furthermore, treatment data recorded in the registers of the&#xD;
      professional societies is analyzed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Guideline compliance</measure>
    <time_frame>2 years</time_frame>
    <description>Guidelines-compliant therapy in patients with chronic CHD (2- or 3-vessel or main vessel disease) according to German National Disease Management Guideline on chronic coronary heart disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart teams</measure>
    <time_frame>2 years</time_frame>
    <description>Frequency and quality of heart teams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient participation</measure>
    <time_frame>2 years</time_frame>
    <description>extent of patient participation in the decision making process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decision making process</measure>
    <time_frame>2 years</time_frame>
    <description>importance of clinical parameters in the decision-making process (e.g. syntax scores, iFR, FFR)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Patients with CHD</arm_group_label>
    <description>outpatient cardiology practices, hospitals with a cardiology department and hospitals with a cardiology and heart surgery department (n=20) in Germany Patients with chronic coronary heart disease and 2- or 3-vessel or main-vessel disease who are being treated at one of the recruitment sites with a promptly planned intervention for myocardial revascularization who are insured with pre-specified German health insurance companies (BARMER or TK)&#xD;
Patients will receive questionnaires.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        outpatient cardiology practices, hospitals with a cardiology department and hospitals with&#xD;
        a cardiology and heart surgery department (n=20) in Germany&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  with chronic coronary heart disease&#xD;
&#xD;
          -  and 2- or 3-vessel or main-vessel disease&#xD;
&#xD;
          -  who are being treated at one of the recruitment sites&#xD;
&#xD;
          -  with a promptly planned intervention for myocardial revascularization&#xD;
&#xD;
          -  who are insured with pre-specified German health insurance companies (BARMER or TK)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Walker, Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>InGef - Institute for Applied Health Research Berlin GmbH; Spittelmarkt 12, 10117 Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Beckmann, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsche Gesellschaft für Thorax-, Herz- und Gefäßchirurgie (DGTHG)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uwe Zeymer, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stiftung Institut für Herzinfarktforschung (IHF)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Ihle</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMV forschungsgruppe, Universitätsklinikum Köln</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ursula Marschall, Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>BARMER</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk Horenkamp, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Techniker Krankenkasse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva-Maria Bitzer, Prof. Dr.</last_name>
    <phone>0049 761 682 142</phone>
    <email>revask@uk-koeln.de</email>
  </overall_contact>
  <link>
    <url>https://revask.de/</url>
    <description>The official website of the REVASK project</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic coronary heart disease</keyword>
  <keyword>myocardial revascularization</keyword>
  <keyword>heart team</keyword>
  <keyword>decision making</keyword>
  <keyword>cardiology</keyword>
  <keyword>heart surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Research data can be shared with persons or institutions with a legitimate scientific interest after consultation in the consortium and only in pseudonymised form and within the scope of the EU-GDPR</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

